text
"['\n1. 요약재무정보\n하기 연결재무정보 및 재무정보는 한국채택국제회계기준에 따라 작성되었으며,제61기(전기)는 종전 기준서인 K-IFRS 1017호에 따라 작성 되었으며, 제60기(전전기)는 종전 기준서인 K-IFRS 1039호, 1018호, 1017호에 따라 작성되었습니다.\n1) 요약연결재무정보\n국제약품(주) 및 종속기업\xa0 \xa0\n(단위 : 원)\n구 분\n제62기\n제61기\n제60기\n[유동자산]\n61,135,035,867\xa0\n54,559,369,036\n59,537,268,607\xa0\n-현금및현금성자산\n7,448,034,125\xa0\n3,658,579,316\n2,526,446,742\xa0\n-매출채권\n20,667,104,826\xa0\n24,356,918,543\n34,631,990,387\xa0\n-재고자산\n16,595,366,817\xa0\n14,183,645,117\n17,161,676,070\xa0\n-기타유동자산\n16,424,530,099\xa0\n12,360,226,060\n5,217,155,408\xa0\n[비유동자산]\n73,458,578,230\xa0\n71,675,526,598\xa0\n72,109,077,814\xa0\n-유형자산\n64,359,978,411\xa0\n61,277,407,372\xa0\n60,644,614,964\xa0\n-무형자산\n1,677,484,748\xa0\n1,872,761,740\xa0\n2,793,348,551\xa0\n-투자부동산\n4,093,469,130\xa0\n4,238,926,338\xa0\n4,384,383,546\xa0\n-기타비유동자산\n3,327,645,941\xa0\n4,286,431,148\xa0\n4,286,730,753\xa0\n자산총계\n134,593,614,097\xa0\n126,234,895,634\xa0\n131,646,346,421\xa0\n[유동부채]\n59,250,771,507\xa0\n48,199,751,500\xa0\n50,577,481,456\xa0\n[비유동부채]\n14,388,889,463\xa0\n9,336,991,512\xa0\n13,290,560,555\xa0\n부채총계\n73,639,660,970\xa0\n57,536,743,012\xa0\n63,868,042,011\xa0\n[자본금]\n18,400,520,000\xa0\n18,057,107,000\xa0\n17,396,596,000\xa0\n[주식발행초과금]\n3,871,568,192\xa0\n3,871,568,192\xa0\n3,871,568,192\xa0\n[기타포괄손익누계액]\n21,480,876,507\xa0\n22,177,699,694\xa0\n22,507,671,905\xa0\n[기타자본항목]\n16,683,166,546\xa0\n16,695,392,877\xa0\n16,712,796,711\xa0\n[이익잉여금]\n492,983,140\xa0\n7,870,638,339\xa0\n7,254,177,296\xa0\n지배기업소유주지분\n60,929,114,385\xa0\n68,672,406,102\xa0\n67,742,810,104\xa0\n비지배지분\n24,838,742\xa0\n25,746,520\xa0\n35,494,306\xa0\n자본총계\n60,953,953,127\xa0\n68,698,152,622\xa0\n67,778,304,410\xa0\n부채와자본총계\n134,593,614,097\xa0\n126,234,895,634\xa0\n131,646,346,421\xa0\n매출액\n111,121,601,008\xa0\n107,681,163,418\xa0\n123,310,224,120\xa0\n영업이익\n5,570,756,961\xa0\n3,287,017,509\xa0\n2,564,176,442\xa0\n당기순이익(손실)\n(4,761,811,946)\n2,182,873,368\xa0\n1,038,655,256\xa0\n\xa01.지배기업소유주지분\n(4,760,904,168)\n2,192,621,154\xa0\n1,092,249,307\xa0\n\xa02.비지배지분\n(907,778)\n(9,747,786)\n(53,594,051)\n기타포괄손익\n(2,384,442,638)\n(558,114,444)\n(321,021,064)\n당기총포괄이익(손실)\n(7,146,254,584)\n1,624,758,924\xa0\n717,634,192\xa0\n\xa01.지배기업소유주지분\n(7,145,346,806)\n1,634,506,710\xa0\n771,288,243\xa0\n\xa02.비지배지분\n(907,778)\n(9,747,786)\n(53,594,051)\n주당순이익(손실)\n(272)\n125\n64\n연결에 포함된 회사수\n1\n1\n1\n<종속기업 재무정보 요약>\n(2019년)\xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0\xa0\n\xa0(단위:천원)\n회사명\n총자산\n자기자본\n매출액\n당기순손익\n케이제이케어(주)\n1,510,709\n465,726\n2,429,926\n(17,021)\n(2018년)\xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0\xa0\n\xa0(단위:천원)\n회사명\n총자산\n자기자본\n매출액\n당기순손익\n케이제이케어(주)\n1,171,994\n482,747\n1,533,821\n(182,771)\n(2017년)\xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0\xa0\n\xa0(단위:천원)\n회사명\n총자산\n자기자본\n매출액\n당기순손익\n케이제이케어(주)\n1,417,804\n665,518\n1,882,224\n(627,664)\n2) 요약재무정보\n국제약품(주)\xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0\xa0\n(단위 : 원)\n구 분\n제62기\n제61기\n제60기\n[유동자산]\n60,161,878,936\xa0\n53,591,579,999\xa0\n58,966,762,270\xa0\n-현금및현금성자산\n7,218,053,324\xa0\n3,343,108,063\xa0\n2,101,785,914\xa0\n-매출채권\n20,233,344,301\xa0\n24,069,101,895\xa0\n34,939,210,196\xa0\n-재고자산\n16,296,426,007\xa0\n13,837,452,079\xa0\n16,747,438,175\xa0\n-기타유동자산\n16,414,055,304\xa0\n12,341,917,962\xa0\n5,178,327,985\xa0\n[비유동자산]\n72,940,313,200\xa0\n71,518,152,473\xa0\n72,056,470,418\xa0\n-유형자산\n64,214,202,193\xa0\n61,144,981,394\xa0\n60,502,977,261\xa0\n-무형자산\n1,674,311,309\xa0\n1,869,588,301\xa0\n2,790,175,112\xa0\n-투자부동산\n4,093,469,130\xa0\n4,238,926,338\xa0\n4,384,383,546\xa0\n-기타비유동자산\n2,958,330,568\xa0\n4,264,656,440\xa0\n4,378,934,499\xa0\n자산총계\n133,102,192,136\xa0\n125,109,732,472\xa0\n131,023,232,688\xa0\n[유동부채]\n59,080,611,261\xa0\n48,116,428,802\xa0\n50,483,528,373\xa0\n[비유동부채]\n14,278,918,866\xa0\n9,281,215,987\xa0\n13,262,882,445\xa0\n부채총계\n73,359,530,127\xa0\n57,397,644,789\xa0\n63,746,410,818\xa0\n[자본금]\n18,400,520,000\xa0\n18,057,107,000\xa0\n17,396,596,000\xa0\n[주식발행초과금]\n3,871,568,192\xa0\n3,871,568,192\xa0\n3,871,568,192\xa0\n[기타포괄손익누계액]\n21,480,876,507\xa0\n22,177,699,694\xa0\n22,507,671,905\xa0\n[기타자본항목]\n16,856,510,473\xa0\n16,868,736,804\xa0\n16,886,140,638\xa0\n[이익잉여금]\n(866,813,163)\n6,736,975,993\xa0\n6,614,845,135\xa0\n자본총계\n59,742,662,009\xa0\n67,712,087,683\xa0\n67,276,821,870\xa0\n자본과부채총계\n133,102,192,136\xa0\n125,109,732,472\xa0\n131,023,232,688\xa0\n종속·관계·공동기업\n투자주식의 평가방법\n원가법\n원가법\n원가법\n매출액\n108,709,297,057\xa0\n106,305,202,738\xa0\n122,290,580,841\xa0\n영업이익\n5,594,782,551\xa0\n2,978,856,968\xa0\n3,409,551,640\xa0\n당기순이익(손실)\n(4,987,038,125)\n1,698,290,969\xa0\n710,891,007\xa0\n기타포괄손익\n(2,384,442,638)\n(558,114,444)\xa0\n-321,021,064\n당기총포괄손익\n(7,371,480,763)\n1,140,176,525\xa0\n389,869,943\xa0\n주당순이익(손실)\n(285)\n97\n41\n']"
